Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-11-23

Clinical Trial Update: A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing valsartan 160 mg vs 320 mg for hypertension has completed. The trial was sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED